Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jagdeep J Vyas, Robert S Brown & Paul J Gaglio. (2003) Hepatitis C–HIV coinfection: current and future therapy. Expert Review of Anti-infective Therapy 1:3, pages 433-439.
Read now
Read now
Articles from other publishers (16)
Ataru Igarashi, Norihiro Furusyo, Eiichi Ogawa, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara & Jun Hayashi. (2019) Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open 9:6, pages e023405.
Crossref
Crossref
Marika Crescenzi, Alberto Tessari, Alessandra Biasiolo, Andrea Padoan, Andrea Gallotta, Giorgio Fassina, Cristina Panciatichi, Oriana Rossetto, Patrizia Pontisso, Daniela Basso & Mario Plebani. (2015) Analytical validation of a Biochip prototype for integrated analysis of AFP-IgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma. Analytical Methods 7:2, pages 629-637.
Crossref
Crossref
Isao Kamae, Hiromitsu Kumada, Masahiro Kobayashi, Thomas Ward, Samantha Webster, Yong Yuan, Anupama Kalsekar, Sachie Inoue, Ann Tang & Phil McEwan. (2014) Epidemiology, treatment and health economics of Hepatitis C in Japan (Review). Kanzo 55:10, pages 589-603.
Crossref
Crossref
Jun Wu, Han Zou, Jing-Ting Jiang, Xiao-Dong Li, Xue-Mei Zhao, Ken Jar, Hong Wang, Bin Xu & Chang-Ping Wu. (2018) Clinical application of serum alpha-fetoprotein-IgM complexes on the diagnosis of primary hepatocellular carcinoma in Kazakh and Han populations. Tumori Journal 99:4, pages 535-539.
Crossref
Crossref
Chao-Hung Hung, Sheng-Nan Lu, Jing-Houng Wang, Tsung-Hui Hu, Chien-Hung Chen, Chao-Min Huang & Chuan-Mo Lee. (2011) Sustained HCV Clearance by Interferon-Based Therapy Reduces Hepatocellular Carcinoma in Hepatitis B and C Dually-Infected Patients. Antiviral Therapy 16:7, pages 959-968.
Crossref
Crossref
Chao‐Hung Hung, Chuan‐Mo Lee, Jing‐Houng Wang, Tsung‐Hui Hu, Chien‐Hung Chen, Chih‐Yun Lin & Sheng‐Nan Lu. (2010) Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon‐based antiviral therapy. International Journal of Cancer 128:10, pages 2344-2352.
Crossref
Crossref
Michael C. Kew. (2010) Prevention of hepatocellular carcinoma. Annals of Hepatology 9:2, pages 120-132.
Crossref
Crossref
Jiang Jingting, Wu Changping, Xu Ning, Zhu yibei, Wu Jun, Ji Mei, Xu Bin, Nilsson‐Ehle Peter & Zhang Xueguan. (2009) Clinical evaluation of serum alpha‐fetoprotein–IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. Journal of Clinical Laboratory Analysis 23:4, pages 213-218.
Crossref
Crossref
Annarosa Floreani, Vincenzo Baldo, Erik Rosa Rizzotto, Isabella Carderi, Tatjana Baldovin & Eliseo Minola. (2008) Pegylated Interferon Alpha-2b Plus Ribavirin for Naive Patients With HCV-related Cirrhosis. Journal of Clinical Gastroenterology 42:6, pages 734-737.
Crossref
Crossref
Wei Wu, Dengfu Yao, Liwei Qiu, Xiaoxiao Gu & Xinhua Wu. (2008) Quantitative analysis of hepatoma-specific α-fetoprotein (HS-AFP) by a new mini-column affinity chromatography and its clinical value in diagnosis of hepatocellular carcinoma. The Chinese-German Journal of Clinical Oncology 7:3, pages 131-134.
Crossref
Crossref
C.‐H. Hung, C.‐M. Lee, S.‐N. Lu, J.‐H. Wang, T.‐H. Hu, H.‐D. Tung, C.‐H. Chen, W.‐J. Chen & C.‐S. Changchien. (2006) Long‐term effect of interferon alpha‐2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis. Journal of Viral Hepatitis 13:6, pages 409-414.
Crossref
Crossref
Chao-Hung Hung, Fang-Ying Kuo, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Chuan-Mo Lee & Hock-Liew Eng. (2005) Impact of Steatosis on Long-Term Histological Outcome in Chronic Hepatitis C after Antiviral Therapy. Antiviral Therapy 11:4, pages 483-489.
Crossref
Crossref
CHAO‐HUNG HUNG, CHUAN‐MO LEE, JING‐HOUNG WANG, HUNG‐DA TUNG, CHIEN‐HUNG CHEN & SHENG‐NAN LU. (2005) Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. Journal of Gastroenterology and Hepatology 20:10, pages 1553-1559.
Crossref
Crossref
Michael C. Kew. (2005) Prevention of hepatocellular carcinoma. HPB 7:1, pages 16-25.
Crossref
Crossref
S.‐N. Lu, H.‐D. Tung, T.‐M. Chen, C.‐M. Lee, J.‐H. Wang, C.‐H. Hung, C.‐H. Chen & C.‐S. Changchien. (2004) Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti‐HCV titre rather than by seroconversion?. Journal of Viral Hepatitis 11:6, pages 563-570.
Crossref
Crossref
Masao Omata, Ryosuke Tateishi, Haruhiko Yoshida & Shuichiro Shiina. (2004) Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127:5, pages S159-S166.
Crossref
Crossref